This study compares the effects of atypical and conventional antipsychotic medications on treatment continuation and outcomes in a first admission sample of patients with schizophrenia treated in usual practice settings. In a sample of 189 participants with a research diagnosis of DSM-IV schizophrenia drawn from the Suffolk County Mental Health Project, we compared the effects of atypical and conventional agents on change of medication, medication gaps, and rehospitalization. For these analyses we used the method of survival analysis for recurrent events, in which the episodes of treatment rather than individual subjects are the units of analysis. In addition, we compared improvement in positive and negative symptoms from intake to 24-or 48-month followups for subjects who stayed on one type of medication or changed to atypicals from conventional antipsychotics. Atypical agents were associated with lower risk of medication change, medication gaps, and rehospitalization. Both conventional and atypical agents were associated with improvement of positive symptoms at followup, but only subjects on atypical agents at followup experienced a significant improvement in negative symptoms. We conclude that in usual practice settings, as in randomized clinical trials, atypical agents are associated with improved treatment continuation and outcomes.
The use of the new generation of antipsychotic medications, generally known as "atypical" or "novel" antipsychotics, has increased dramatically over the past decade. The first medication in this series was clozapine, which, because of the higher risk of agranulocytosis, found limited application in routine clinical practice. Atypical agents introduced in more recent years, such as risperidone, olanzapine, and quetiapine, have not been associated with an increased risk of this side effect and were shown in clinical trials to be at least as efficacious as conventional antipsychotics for schizophrenia and other psychotic disorders (Remington and Chong 1999; Worrel et al. 2000) . Randomized clinical trials have also shown that patients treated with these medications have fewer extrapyramidal symptoms and, as a result, have better adherence, fewer gaps in treatment, and fewer rehospitalizations (Dellva et al. 1997; Tran et al. 1998; Conley et al. 1999; Rosenheck et al. 2000) .
Results from randomized clinical trials, however, are not always replicated in usual care settings (Brugha et al. 1992; Weisz et al. 1995) . Real-world effects are best assessed in naturalistic studies of representative samples. There are few such studies examining atypical antipsychotic medications (Coley et al. 1999) , and it is not clear whether the better side effect profiles and efficacy of atypical agents in experimental settings translate into improved compliance and effectiveness for patients in the community-especially patients in early stages of their illness.
The present study examined these effects in an epidemiological sample of subjects with first admission schizophrenia. We first compared rates of change in medication, gaps in medication use, and rehospitalization while on medication among individuals receiving conventional and atypical agents. Next, we compared patients on conventional and atypical antipsychotics at 24-or 48-month followups with regard to positive and negative symptoms.
Method
Sample. The data were drawn from the Suffolk County Mental Health Project (SCMHP), a longitudinal study of consecutive first admissions to 12 psychiatric facilities in Send reprint requests to Dr. Ramin Mojtabai, 2600 Netherland Ave., Apt. #805, Bronx, NY 10463; e-mail: rm322@columbia.edu.
Suffolk County, NY. Study participants were recruited between September 1989 and December 1995, and the 48-month followup of the sample extended to 1999. Inclusion criteria were age between 15 and 60, residence in the county, and clinical evidence of psychosis (for a detailed description of SCMHP, see Bromet et al. 1992) . Exclusion criteria were a psychiatric hospitalization more than 6 months before the current admission, moderate or severe mental retardation, and inability to speak English. Overall, 674 (72%) individuals who met the inclusion criteria agreed to participate in the study. Written informed consent was obtained for participation in the study and for getting information from medical records and significant others.
Following the intake interview, participants were interviewed by phone every 3 months and in person at 6, 24, and 48 months. Eighty-nine percent of the participants were assessed at 24-month followup and received a 24-month consensus research diagnosis. Eighty-two percent were assessed at the 48-month followup. The sample for the present study comprised 189 participants with a consensus 24-month diagnosis of DSM-IV schizophrenia (American Psychiatric Association 1994).
Instruments.
At intake and at each face-to-face followup interview, participants were interviewed with the Structured Clinical Interview for DSM-IH-R (SCID) (Spitzer et al. 1992) . The average interrater reliability estimate (kappa) for ratings of current psychotic symptoms on SCTD was 0.74, corresponding to rates of agreement of more than 95 percent (Bromet et al. 1992 ). In addition, after each followup, the interviewers completed the Scale for the Assessment of Positive Symptoms (SAPS) (Andreasen 1984) and the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen 1983) . The SAPS includes ratings of hallucinations, delusions, bizarre behavior, and thought disorder. The SANS includes ratings of affective flattening, alogia, avolition, anhedonia, and attention. Interviewers were not blinded to participants' treatment status.
Project psychiatrists formulated DSM-IV consensus diagnoses by integrating the SCTD scores, information in the medical records, interviewers' clinical ratings, and information from significant others (Schwartz et al. 2000) .
Medication
Use. All conventional antipsychotic medications were available before September 1989, when the first participant was enrolled. Clozapine became available for treatment of psychosis in April 1991 , risperidone in February 1994 , olanzapine in October 1996 , and quetiapine in October 1997 . Medication use data were recorded on the Suffolk Psychopharmacology Epidemiologic Chronology (SPEC) after reviewing all sources of information, including clinical records and interview materials (SPEC manual available from the fourth author). The information included names of medications, daily doses, and start and stop dates. Guidelines for estimating missing dates were developed. For example, if the participant indicated that he or she started taking medication in "early," "mid," or "late" September, the start dates were recorded as September 5, 15, or 25, respectively. The reliability of the self-reports was established in a study comparing the participants' reports with information from the medical records (Gibson et al. 1999) .
The present study focused on three types of events during the course of treatment:
1. Changes in antipsychotic medication, defined as changes within categories (e.g., from one conventional agent to another or from oral to depot) or across categories (e.g., from a conventional to an atypical agent). 2. Gaps in antipsychotic medication use, defined as a period of 2 weeks or longer during which the patient received no antipsychotic medication. The choice of 2 weeks was based on results of previous studies indicating that patients who stop antipsychotic medications for 1 week or less are likely to resume taking medication (Weiden et al. 1995) . The analyses were also performed using two alternative definitions of gap, 1 week or longer and 1 month or longer. The results were similar to those reported here. 3. Rehospitalization while on antipsychotic medications, defined as any inpatient admissions while receiving antipsychotic medications.
Analysis. Cox regression for recurrent events ) was used for the analyses of time to medication change, gaps in medication use, and rehospitalization. While the method of survival analysis for recurrent events has been widely used in other fields of medicine (Wassell et al. 1999; Kelly and Lim 2000) , it has rarely been used in psychiatry. This is surprising because the outcomes of interest in psychiatry are often recurrent events such as relapses or rehospitalizations. The units of analysis for the survival analyses reported in this study were episodes of medication use. An episode was defined by change in medication or change in dose of medication. Thus, the analyses take account of change in dose as well as type of medication. In addition, the variable of time since intake into study was entered into the analyses for all three outcomes, and the variables of the number of previous medication changes, medication gaps, and rehospitalizations were entered into the analyses for corresponding outcomes.
Most patients had multiple episodes of medication use, and many experienced the events of interest (i.e., change in medication, gaps in medication use, and rehospitalization) multiple times. Because medication episodes for the same individuals are not independent, analyzing these data with the usual Cox regression methods would produce erroneous standard error estimates for the regression parameters. Lin and Wei (1989) proposed a method for correcting the standard errors when analyzing such data. For the Cox regression analyses reported here, we used the Lin and Wei method as implemented in the Stata 7.0 software (StataCorp 2001) .
In these analyses, time to event is calculated from the onset of each medication episode to the time when the individual develops the event of interest or has a dose change. When each event of interest is analyzed, other events are considered as "censoring." For example, when rehospitalization was analyzed, medication episodes that ended in change of medication or gaps in medication use were considered censored observations. This approach to analyzing different outcomes has been discussed by Blossfeld et al. (1989) under "multistate models." According to these authors, "When observing a specific type of event (or a specific destination state), the realization of multistate models is achieved by regarding the competing events as censored" (p. 168).
Analyses were conducted in two stages. First, we examined the effects of different variables in a series of bivariate analyses. Next, we used multivariate models to examine the effects of medication type, controlling for the potential confounders-that is, variables that were significant in bivariate analyses. Variables were retained or removed from the multivariate models based on the statistical significance (p <, 0.05) of the Wald test associated with each variable. As the main question of this study was the effect of atypical antipsychotic medications and other variables were entered in the analyses to control for their confounding effects, no correction for multiple testing was used. When exponentiated, regression coefficients from the Cox regression model can be interpreted as the ratio of the hazard rate for each group over the hazard rate for the reference group, where hazard rate is the probability that a person at risk for an event (e.g., change of medicine, hospitalization, etc.) at the beginning of a time interval would experience that event during that interval.
Analyses examining changes in SAPS and SANS as a function of medication type were limited to participants with face-to-face interviews at 24 or 48 months who received antipsychotic medications both at intake and at one of these followups (n = 119). For participants who had a 48-month followup, data from this time point were used. For those without a 48-month followup, data from the 24-month followup were used. Participants were categorized in three nonoverlapping groups: (1) on conventional antipsychotics at intake and at followup (n = 92); (2) on conventional antipsychotics at intake and atypical agents at followup (/i = 19); and (3) on atypical antipsychotics at intake and at followup (n = 8). There were no significant differences between groups 1 and 2 in the proportion with 48-month followup (68.5% vs. 78.9%, respectively, x 2 = 0.83, df= \,p = 0.36). Only 1 (12.5%) of the 8 in group 3, however, had a 48-month followup; the remainder had 24-month followups. Paired t tests were used to compare intake and followup symptom scores within each of the three groups. Given the small number of subjects in groups 2 and 3, we knew that statistical tests alone might not reflect the clinical significance of the effects. Therefore, effect sizes (mean change divided by standard deviation of change) were also calculated.
Results
Demographic and Psychiatric Characteristics of the Sample. The average age of the 189 participants was 28.8 (standard deviation [SD] = 8.9). The majority were male (68%), were non-Hispanic white (71%), had never married (78%), and had graduated from at least high school (73%). The median delay between first psychotic symptoms and first hospitalization was 301 days. For 45 percent, this delay was a year or longer. At the time of baseline interview, 44 percent had a diagnosis of lifetime alcohol or substance use disorder. The first admission was in a state hospital for 40 percent, in the Stony Brook university hospital for 30 percent, in a community hospital for 22 percent, and in other types of facilities for 9 percent (percentages add to more than 100% because of rounding error). There were statistically significant differences between facility types with regard to prescription of atypical agents: 19 percent of the patients whose first admission was in a community hospital received atypical agents compared to 6 percent of patients in the university hospital, 1 percent of those in state hospitals, and 0 percent in other facility types (x 2 = 14.10, df=3,p = 0.003). There were no statistically significant differences among facility types on the use of conventional oral antipsychotic medications and depot agents. The mean length of followup was 43.3 months (SD =18.1).
Type and Dose of Antipsychotic Medications Used
During the Followup Period. Only 19 percent of the 189 subjects remained on one kind of conventional or atypical antipsychotic medication throughout the followup. Others experienced from 1 to 11 changes in medications, with a median of 3 changes. Overall, there were 438 medication changes. Ninety-eight percent of the participants received an oral conventional antipsychotic, including haloperidol (58%), fluphenazine (31%), perphenazine (28%), chlorpromazine (14%), droperidol (7%), pimozide (2%), loxapine (2%), mesoridazine (2%), molindone (2%), and chlorprothixene (1%). Thirty-three percent received depot antipsychotics, including haloperidol decanoate (20%) and fluphenazine decanoate (17%). Finally, 30 percent received an atypical agent, including risperidone (22%), olanzapine (9%), clozapine (7%), and quetiapine (1%). Because most subjects changed medication a number of times during the followup, the above percentages add up to more than 100 percent.
The average chlorpromazine equivalent dose (Zito 1994; Aitchison et al. 1999 ) was 340.5 mg/day (SD = 251.9 mg/day). The average dose was less than 300 mg/day for 54 percent, between 300 and 599 mg/day for 33 percent, between 600 and 999 mg/day for 11 percent, and greater than or equal to 1000 mg/day for 3 percent As a benchmark, the recommended dose for maintenance treatment of schizophrenia is 300 to 600 mg/day (Lehman et al. 1998 ).
Medication Gaps and Rehospitalization While on
Medication. Sixty-five percent of the 189 participants experienced at least one gap of 2 weeks or longer in antipsychotic medication treatment. Overall, there were 209 such gaps. Thirty percent experienced more than one gap. One hundred and twenty-nine (68.2%) of the participants experienced rehospitalizations during the followup period. Forty-one (21.7%) were rehospitalized while taking antipsychotic medications. Overall, there were 62 episodes of rehospitalization while on medication.
Predictors of Medication Change, Medication Gaps, and Rehospitalization. The use of atypical antipsychotics was significantly associated with lower rates of medication change, medication gaps, and rehospitalization, even after controlling for the effects of various sociodemographic and psychiatric characteristics as well as the characteristics of the medication use episodes (table  1) . Relative to oral conventional antipsychotics, depot medications were associated with a lower rate of medication change but not lower rates of gaps or rehospitalizations, after controlling for other effects.
The same findings are presented graphically in the form of survival curves in figure 1. Depot medications were combined with conventional oral medications in this figure's data.
A number of other variables were also associated with outcomes of interest in multivariate analyses. As would be expected, previous multiple medication changes (£ 3 changes) were associated with an increased likelihood of experiencing future change in medications, but age over 25 years at baseline and medication episodes that started after the first month following intake were associated with lower risk of medication change (table 1) .
Variables associated with an increased risk of medication gaps in multivariate analysis included lower education and multiple previous gaps (S 3 gaps). More severe negative symptoms at intake were associated with lower risk of gaps, as were medication episodes that started 24 months or later after intake.
Variables associated with an increased risk of rehospitalization in multivariate analysis included medication doses larger than 1000 mg/day and any previous rehospitalizations. The effect of higher dose may simply be an indication of the start of a new episode of illness, which leads the clinician to raise the dose and, failing to control the illness in the outpatient setting, to hospitalize the patient. In contrast, individuals on conventional antipsychotics at both intake and followup showed no significant improvement on negative symptoms (figure 2b) (intake SANS mean = 2.00 [SD = 0.95], followup mean = 1.86 [SD = 0.89], effect size = 0.13, paired t = 1.23, df =91, p = 0.22), but those receiving conventional antipsychotics at intake and atypical antipsychotics at followup experienced a significant improvement (intake SANS mean = 2.13 [SD = 0.89], followup mean = 1.53 [SD = 0.98], effect size = 0.52, paired t = 2.29, df= 18, p = 0.03). Improvement in negative symptoms among participants who were on atypical antipsychotics at both time points was similar in magnitude to the latter group but because of the small number of subjects, the difference was not statistically significant (intake SANS mean = 2.45 [SD = 1.11], followup mean = 1.92 [SD = 0.96], effect size = 0.42, paired / = 1.18, # = 7, p = 0.28).
Discussion
Randomized clinical trials comparing atypical and conventional antipsychotic medications generally report equal or superior efficacy for atypical agents (Remington and Chong 1999; Worrel et al. 2000) . Results of the present One caveat in interpreting these findings is the possibility of selection bias. It is possible that certain subject characteristics that are associated with more favorable outcomes also led the treating clinicians to prescribe atypical antipsychotics. If so, those characteristics and not the type of medication per se would be responsible for the observed favorable effects. To assess this possibility, we repeated the analyses by limiting the sample to 53 (28%) subjects who had received both conventional and atypical antipsychotics at different time points during their followup. This reduced the possible effects of selection bias because conventional and atypical agents were compared in the same subjects. The results of these analyses were quite similar to the main analyses of the study. Most participants who received atypical medications in this study were started on conventional agents. Inadequate response to conventional medications was likely a major reason for the switch to atypical agents. While most of the currently available atypical agents became available during the period covered by this study, these medications found widespread use in only more recent years, and at the time of the study the original atypical agent, clozapine, was used mostly for patients with treatment-resistant schizophrenia. Because of wider availability of atypical agents in more recent years and accumulating data on their safety and superior side effect profiles, many non-treatment-resistant patients are now being switched to atypical agents. Future followups of this cohort of patients could therefore clarify whether the positive effects of atypical agents are limited to treatment-resistant patients or generalize to all patients. We also note that the variables of the number of previous medication changes, medication gaps, and rehospitalizations, which are indicators of past treatment failures, did not explain away the beneficial effects of atypical agents in the multivariate analyses (table 1) .
Another consideration in interpreting these results is the possible effects of close monitoring and regular blood tests required for treatment with clozapine. Frequent contact with medical providers because of such monitoring may reduce the risk of medication gaps or other adverse events in the course of treatment Thus, the observed lower rates of adverse events for atypical agents may be limited to clozapine. To evaluate this possibility, we repeated the regression analyses including separate indicator variables for clozapine and other atypical agents in the model. The results of these analyses confirmed that the lower rates of adverse events were not limited to clozapine. The use of other atypical medications was also associated with lower rates of medication change (for clozapine HR = 0.40, 95% CI = 0.21-0.78, p = 0.007; for other atypical agents HR = 0.60, 95% CI = 0.40-0.90, p = 0.01), gaps in medication use (for clozapine HR = 0.10, 95% CI = 0.01-0.75, p = 0.03; for other atypical agents HR = 0.52, 95% CI = 0.32-0.85, p = 0.009), and rehospitalization (for clozapine HR = 0.41, 95% CI = 0.06-2.91, p = 0.37; for other atypical agents HR = 0.14, 95% CI = 0.02-1.02, p = 0.05).
The effect of atypical antipsychotics on medication change and gaps may be a result of the superior side effect profile of these medications, as gaps in treatment and change of medication often result from intolerable side effects or lack of response to treatment (Rosenheck et al. 2000) . The effect of gaps in antipsychotic medication treatment on the risk of future relapses is well documented (Gilbert et al. 1995) . A study of first admission schizophrenia patients found a fivefold increase in the rate of psychotic relapses after stopping antipsychotic medications (Robinson et al. 1999) . Similar increases in the rate of rehospitalization after stopping medications were reported in the SCMHP cohort . Such discontinuities in treatment are common in schizophrenia (McCombs et al. 1999) , especially in the early stages of illness (Novak-Grubic and Tavcar 1999), with possible long-term effects (Wyatt et al. 1998) . Thus, improved continuity of care in the early stages of illness through greater use of atypical agents along with interventions for improving treatment compliance (Olfson et al. 1998; Spooren et al. 1998 ) could enhance the long-term course of illness.
In addition to their indirect effect on rehospitalization rates dirough improved continuity of treatment, atypical antipsychotics appear to directly reduce the risk of rehospitalization, as indicated by the results of this study and other studies (Essock et al. 1996; Dellva et al. 1997; Tran et al. 1998; Conley et al. 1999; Rvicki 1999; Rabinowitz et al. 2001) . As the hospitalization costs comprise a large proportion of the treatment costs of schizophrenia (Rice and Miller 1996; Young et al. 2001) , reduction in hospital use would have an important impact on the overall costs of the illness.
One caveat in interpreting the effects of atypical antipsychotics on symptom outcomes in the present study is again the possibility of selection bias. Clinicians may be more likely to prescribe atypical antipsychotics for patients with more pronounced negative symptoms based on the reports of superior effects of atypicals for these symptoms. On the other hand, subjects with more pronounced negative symptoms may experience a larger reduction in SANS scores simply because of "regression toward the mean." Consistent with this explanation, the SANS scores were somewhat higher among participants who were started on atypical agents at intake or were later switched to these medications, although the difference across groups was not statistically significant. However, our results correspond to findings from a number of clinical trials that report better response of negative symptoms to atypical antipsychotic medications compared with conventional agents (Mbller 1999; Remington and Chong 1999; Worrel et al. 2000) .
Although atypical agents have a better side effect profile and may be more effective on some dimensions of illness, they are more expensive than conventional antipsychotic medications (Fichtner et al. 1998) . For example, the cost of maintenance treatment on risperidone (4-8 mg/day dose) would currently be $240 to $380 per month, whereas maintenance on haloperidol (1-15 mg/day dose) would cost $9 to $45 per month (Ellsworth et al. 2001) . The cost of medications, however, is only a small proportion of the total cost of schizophrenia (Rice and Miller 1996; Young et al. 2001) . Part of the higher cost of atypical medications may well be offset by reductions in hospital use (Hamilton et al. 1999; Obenchain and Johnstone 1999) , and by reduction in morbidity and functional impairment. More important, the benefits of the improved quality of life associated with the use of atypical agents may far exceed the monetary costs of these medications.
